SCHEMBL6132904

SCHEMBL6132904

OC/C=C\c1cccnc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 2/20 0.59
CYP11B1 P15538 1/20 0.59
KMT2A Q03164 4/20 0.57
CHRNB2 P17787 2/20 0.57
CHRNA4 P43681 2/20 0.57
MEN1 O00255 2/20 0.57
CHRNB4 P30926 1/20 0.57
CHRNA3 P32297 1/20 0.57
CHRNA7 P36544 1/20 0.57
CYP2D6 P10635 1/20 0.57
CYP2C9 P11712 1/20 0.57
ALOX15 P16050 1/20 0.57
CYP2C19 P33261 1/20 0.57
RAB9A P51151 3/20 0.56
MAPT P10636 3/20 0.56
NPC1 O15118 2/20 0.56
MAPK1 P28482 2/20 0.56
KDM4E B2RXH2 1/20 0.56
JUN P05412 1/20 0.56
NFKB1 P19838 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6132907 1.00 CYP11B2 (0.59) CYP11B2CYP11B1KMT2ACHRNB2CHRNA4
SCHEMBL6133106 1.00 CYP11B2 (0.59) CYP11B2CYP11B1KMT2ACHRNB2CHRNA4
SCHEMBL22978671 0.82 TBXAS1 (0.66) CYP11B2CYP11B1KMT2ACHRNB2CHRNA4
SCHEMBL7099093 0.82 CYP11B2 (0.61) CYP11B2CYP11B1KMT2ACHRNB2CHRNA4
SCHEMBL7099087 0.82 CYP11B2 (0.61) CYP11B2CYP11B1KMT2ACHRNB2CHRNA4
SCHEMBL6848092 0.80 MKNK1 (0.57) CYP11B2CYP2D6CYP2C9CYP2C19ALDH1A1
SCHEMBL9265153 0.80 TBXAS1 (0.68) CYP11B2CYP11B1KMT2ACHRNB2CHRNA4
SCHEMBL6848095 0.80 MKNK1 (0.57) CYP11B2CYP2D6CYP2C9CYP2C19ALDH1A1
SCHEMBL9265164 0.80 TBXAS1 (0.68) CYP11B2CYP11B1KMT2ACHRNB2CHRNA4
SCHEMBL29691639 0.80 CYP11B1 (0.86) CYP11B2CYP11B1KMT2ACHRNB2CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6924278-B2 Heterocyclic carboxy amines such as (2R)-1-[3,5-Bis(trifluoromethyl)benzoyl]-4-[4-((3S)-3-ethylmorpholino)-2-butynyl]-2-[(1H-indol-3-yl)methyl]piperazine, used as substance P and neurokinin antagonist for prophylaxis of diseases FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-08-02 US disclosed
US-20050027121-A1 Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-02-03 US disclosed
US-20030114668-A1 AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-19 US disclosed
EP-0993457-A1 AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-04-19 EP disclosed
WO-1998057954-A1 AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050027121-A1 Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists TAC3, TACR1, SSTR5 CYP11B2 2036/4885CYP11B1 2668/4885KMT2A 829/4885
US-20030114668-A1 AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS TACR1, NPSR1, SSTR2 CYP11B2 1363/4885CYP11B1 1566/4885KMT2A 1097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.